- Trial phase
- Approved
- Time to market
- Already approved and marketed (COPD since 2017, asthma since 2020)
- Why 4/10
- Trelegy Ellipta is already FDA-approved and commercially marketed for both COPD (2017) and asthma (2020). There is no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The next hard catalyst is a $100M milestone payment expected in Q1 2027, which is a contractual payment, not a regulatory binary. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and GSK is a large diversified pharma where Trelegy is one of many products.
Trelegy Ellipta is already approved and generating revenue, there is no near-term binary catalyst for GSK stock from this drug. Watch for Q1 2027 when a $100M milestone payment is expected from Theravance/Zymeworks, and monitor quarterly sales trends for signs of erosion from competitors like AstraZeneca's Breztri Aerosphere.
Price Chart
Executive Summary
Trelegy Ellipta is GSK's once-daily single-inhaler triple therapy (ICS/LAMA/LABA) for COPD and asthma, first FDA-approved in September 2017 for COPD and expanded to asthma in September 2020. It was the first product of its kind approved in the US and is supported by robust Phase 3 data including the landmark IMPACT trial. As an already-approved, commercially established product, Trelegy generates significant revenue for GSK but offers no near-term binary catalyst. GSK is a large diversified pharma with a 'hold' analyst consensus and ~6.8% implied upside. The next notable event is a $100M milestone payment expected in Q1 2027 from the Theravance/Zymeworks transaction.
How It Works
Trelegy Ellipta is a once-daily inhaler that combines three drugs in a single device: an inhaled corticosteroid (ICS) to reduce airway inflammation, a long-acting muscarinic antagonist (LAMA) to relax airway muscles, and a long-acting beta agonist (LABA) to keep airways open. Together they treat both COPD and asthma by targeting different pathways involved in airway narrowing and inflammation.
Trial Status
Trelegy Ellipta is FDA-approved and commercially available. Pivotal Phase 3 trials (IMPACT, FULFIL) have been completed and published. Ongoing studies focus on real-world effectiveness (INTREPID) and incremental label positioning rather than new active indications.
The Two-Sided Case
Upcoming Catalysts
- $100M milestone payment from Theravance/Zymeworks expected in Q1 2027
- Quarterly sales trends and market share vs. competitors like AstraZeneca's Breztri Aerosphere
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report